QHSLab, Inc.
Close on Oct 19, 2026
- Market cap
- $7.38M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
QHSLab has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements QHSLab filed with the SEC
(OTCQB:USAQ) Reports Second Quarter and First Half 2026 Unaudited Financial Results
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Update – May 26, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment
Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) Reports Strong Fiscal 2025 Results with Revenue Growth, Expanding Margins, and Significant Balance Sheet Improvement
Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt
Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) Initiates Board Expansion Process to Strengthen Governance and Support Next Phase of Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session
Regulation FD disclosure · EX-99.1 to Form 8-K
QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) Announces Launch of Q-Cog™ to Support Early Detection of Mild Cognitive Impairment and Dementia
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
A Transformational Quarter: Rapid Growth, Strengthened Balance Sheet, and a Powerful Setup for 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
QHSLab (OTCQB:USAQ) Completes Repurchase of Legacy
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB: USAQ) Rolls Out Breakthrough Pediatric Screening Tool Linking Allergies and Mental Health
Regulation FD disclosure · EX-99.1 to Form 8-K
Healthcare, Powered by QHSLab, Inc. (OTCQB: USAQ), Opens Doors in Miami to Expand Access to Mental Health Services
Regulation FD disclosure · EX-99.1 to Form 8-K
Healthcare, impulsado por QHSLab, Inc. (OTCQB: USAQ), abre sus puertas en Miami para ampliar el acceso a servicios de salud mental
Regulation FD disclosure · EX-99.2 to Form 8-K
Inc. Publishes Peer-Reviewed Studies Validating Digital Tools for Enhancing Patient
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
QHSLab, Inc. Reports 32% Year-Over-Year
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Engages Hayden IR to Launch Comprehensive Investor Relations Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Record Revenue Growth and Positive Net Income in Preliminary Q4 and FY 2024 Financial Results
Regulation FD disclosure · EX-99.1 to Form 8-K
and Town Total Compounding Announce Strategic Co-Marketing Partnership to Expand Market Opportunities and Drive Organic Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
light of recent inquiries from interested potential investors, I wanted to address some important questions about our business model
Regulation FD disclosure · EX-99.1 to Form 8-K
(OTCQB:USAQ) and South Dakota State University Celebrate NSF Invitation to Submit STTR Application for AIR-GUIDDE Technology
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. (OTCQB: USAQ) Marks Major Achievements in Digital Health Innovation, Research Recognition, and Revenue Growth in 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. (OTCQB: USAQ) Reports Record Q3 2024 Revenues, Reflecting Accelerated Expansion in Digital Health and Allergy Diagnostics
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Welcomes Dr. Juan D. Oms, MD, FAPA, as Medical Advisor for Psychiatry and Behavioral Health
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
we have entered the final quarter of 2024, I want to take a moment to reflect on what we’ve achieved this year and outline our
Regulation FD disclosure · EX-99.1 to Form 8-K
Secures Grant Sponsorship from a Global Leader in Consumer Health to Advance Digital Medicine Tools for Allergy Management in the Primary
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Major Research and Development Milestones for 2024: Doubling Assessment Completion and Advancing Digital Medicine Innovation
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Strong Second Quarter and Six-Month 2024 Results
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Strong First Quarter 2024 Results with Significant Reduction in Operating Expenses and Positive Net Operating Income
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Enhances Leadership Team with Dr. Marcos Sanchez-Gonzalez as New VP of Medical and Scientific Affairs
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Preliminary Unaudited First Quarter Revenue Results
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
Regulation FD disclosure · EX-99.1 to Form 8-K
excited to inform you of a significant achievement at QHSLab: our successful integration with athenahealth’s Electronic Medical
Regulation FD disclosure · EX-99.1 to Form 8-K